Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Litton

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
The Breast Journal|December 13, 2012
Genotype in BRCA-associated breast cancersFunda Meric-Bernstam, Angelica M Gutierrez-Barrera, Jennifer Litton, et al.
Cancer|June 22, 2010
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicityMariana Chavez-Macgregor, Jennifer Litton, Huiqin Chen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 22, 2010
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomyMin Yi, Kelly K Hunt, Banu K Arun, et al.
Cancer|October 20, 2011
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situSoley Bayraktar, Nisreen Elsayegh, Angelica M Gutierrez Barrera, et al.
Hormones & Cancer|July 16, 2011
Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancerJie Qing Chen, Yi Bao, Jennifer Litton, et al.
Hormones & Cancer|July 16, 2011
Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancerJie Qing Chen, Jennifer Litton, Li Xiao, et al.
The Lancet. Oncology|April 19, 2014
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialFabrice André, Ruth O'Regan, Mustafa Ozguroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionShiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.
American Journal of Cancer Research|March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancerYu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
The Breast Journal|December 13, 2012
Genotype in BRCA-associated breast cancersFunda Meric-Bernstam, Angelica M Gutierrez-Barrera, Jennifer Litton, et al.
Cancer|June 22, 2010
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicityMariana Chavez-Macgregor, Jennifer Litton, Huiqin Chen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 22, 2010
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomyMin Yi, Kelly K Hunt, Banu K Arun, et al.
Cancer|October 20, 2011
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situSoley Bayraktar, Nisreen Elsayegh, Angelica M Gutierrez Barrera, et al.
Hormones & Cancer|July 16, 2011
Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancerJie Qing Chen, Yi Bao, Jennifer Litton, et al.
Hormones & Cancer|July 16, 2011
Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancerJie Qing Chen, Jennifer Litton, Li Xiao, et al.
The Lancet. Oncology|April 19, 2014
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialFabrice André, Ruth O'Regan, Mustafa Ozguroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionShiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.
American Journal of Cancer Research|March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancerYu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.
Pageof 3